Results

1–10 of 25 results for drug delivery

Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022
Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis
Christopher R Henry, MD
Annual Meeting Talks
2022
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Post Hoc Analysis of Suprachoroidal CLS-TA Versus Real-World Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function
Steven Yeh, MD
Annual Meeting Talks
2021
Suprachoroidal Delivery of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes
James C. Major, MD, PhD FACS FASRS
Annual Meeting Talks
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE Study
Dennis M. Marcus, MD
Annual Meeting Talks
2021
A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS
Annual Meeting Talks
2021
Microscope-Integrated Optical Coherence Tomography Can Measure the Volume of Subretinal Blebs Created by a Suprachoroidal Approach
Ananth Sastry, MD
Annual Meeting Talks
2020